Payment overview · 2025
General Payments
$373.50
14 reported records · 10 companies
Healthcare provider profile · identity verified
Ryon Eugene Parker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1609001759
Verified facts
What the public records show
CMS Open Payments records show Ryon Eugene Parker, MD received $373.50 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xolair by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.09 | 26.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $54.63 | 14.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.76 | 13.1% | 2 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $47.86 | 12.8% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $29.07 | 7.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.85 | 6.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.61 | 5.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.99 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.43 | 4.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.21 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $373.50 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.09 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.14 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $54.63 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $48.76 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $47.86 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 151 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 20 |
| Metformin Hcl | Metformin Hcl | 80 | 29 |
| Losartan Potassium | Losartan Potassium | 58 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 16 |
| Azithromycin | Azithromycin | 51 | 38 |
| Montelukast Sodium | Montelukast Sodium | 49 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 12 |
| Gabapentin | Gabapentin | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Lisinopril | Lisinopril | 37 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 16 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 16 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | 11 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Furosemide | Furosemide | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Edarbi | Azilsartan Medoxomil | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 22 | suppressed |
| Prolia | Denosumab | 22 | 11 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Prednisone | Prednisone | 20 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 17 |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Xolair | Omalizumab | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Cephalexin | Cephalexin | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Plavix | Clopidogrel Bisulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $373.50 · 14 records | Novo Nordisk Inc | AIRSUPRA, Cleerly Labs, FREESTYLE LIBRE 3, LEQVIO, OTEZLA, Ozempic, REPATHA, Rybelsus, VOQUEZNA, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error